ClinicalTrials.gg
RecruitingNCT07645235Updated Sep 30, 2026

A Study to Evaluate Gepotidacin Exposure in Breast Milk of Healthy Lactating Women

A Phase 1 interventional study of Gepotidacin in Urinary Tract Infections, sponsored by GlaxoSmithKline. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Sep 30, 2026Now RecruitingFirst site in United States+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Urinary Tract Infections by GlaxoSmithKline — 4 open to participants now, 4 under way, none of them phase 3. Urinary Tract Infections · GlaxoSmithKline.

Planned enrollment
13th of 13
8 · median 61
Started
2026
with 2 others
Phase 1
5 of 14
2 open now
Registered
13th of 14
by date

Among the 14 studies in Urinary Tract Infections by GlaxoSmithKline, this one is the 13th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2026, is one of 5 in phase 1, and was the 13th registered.

Urinary Tract Infections

804 studies on the registry are indexed under Urinary Tract Infections; 133 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

4 of the 14 studies in Urinary Tract Infections by GlaxoSmithKline are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 84 Urinary Tract Infections studies recruiting now, 50 (60%) set no upper age limit and 23 (27%) stop at 75 or younger; 15 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 50 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Urinary Tract Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

This study aims to evaluate the pharmacokinetic of gepotidacin in fed healthy lactating women.

03

Conditions studied

  • Urinary Tract Infections

Keywords

  • Gepotidacin
  • Pharmacokinetics
  • Healthy Lactating Women
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be healthy lactating women, 18 to 50 years of age, inclusive, at Screening.
  • Actively breastfeeding or expressing breast milk.
  • At least 28 days postpartum with a full milk supply established, and with no persistent complications from delivery (there is no maximal length of time postpartum required).
  • Willingness to temporarily discontinue feeding breast milk to infants from dosing through to 72 hours after dosing (approximately 3 days), with the ability to pump and provide reserve milk for bottle feeding prior to the study OR has decided to permanently discontinue breastfeeding but has not started weaning, provided the infant accepts bottle feeding and a sufficient milk supply is maintained by pumping 3 to 4 times daily, considering changes in milk composition during weaning process.
  • Is willing to fully express breast milk from both breasts during the duration of the milk collection portion of the study. Participants must be able to express milk from each breast at each pumping session using a breast pump.
  • Has a (BMI) of less than or equal to (\<=) 36 kilograms per meter square (kg/m\^2) and weighs at least 45 kilograms (kg) with all clinical assessments considered as clinically non-significant per investigator.
  • Non-smoker (including vaping) or prior smokers (having smoked less than 10 cigarettes per day) who have stopped smoking for at least 1 month prior to screening.
  • Understands the study procedures and is capable of providing written .
  • A negative highly sensitive pregnancy test ([urine or serum] as required by local regulations) will be required at Baseline before the dose of study intervention.

Exclusion criteria

Exclusion Criteria:

  • Participant is unwilling or unable to comply with the study restrictions or lifestyle guidelines presented in the protocol during the study period and through the post study visit.
  • History or evidence of any hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, psychiatric (including post-natal depression), neurologic, infectious, neoplastic, active cancer or allergic disease (including drug allergies, but excluding untreated asymptomatic, seasonal allergies at time of dosing) or clinical findings that, in the opinion of the study investigator, might confound the results of the study or poses an additional risk to the participant or infant by participation in the study.
  • Has had major surgery in the past 3 months (except delivery through a C section and/or tubal ligation).
  • History of significant multiple and/or severe allergies (including latex allergy, but with exception of seasonal rhinitis [hay fever]) or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food.
  • to gepotidacin.
  • Current or recent (less than [\<] 14 days) mastitis, or history of breast surgery (augmentation or reduction).
  • Use of any prolonging medications within 7 days prior to first dose, use of strong or moderate Cytochrome P450 3A4 () inhibitors within 7 days prior to first dose, or use of strong or moderate CYP3A4 inducers (including vitamins, herbal and dietary supplements such as St. John's wort) within 14 days prior to first dose.
  • Currently a user of illicit drugs or has a history of drug (including alcohol) abuse within approximately 1 year.
  • Donated or lost 1 unit of blood (approximately 500 milliliters [mL]) or participated in another study within 30 days or 5 half-lives of the investigational product prior to the screening. The 30 days window will be derived from the date of the last study procedure (i.e., poststudy, AE follow-up, etc.) in the previous study to the screening visit of the current study.
  • The participant has participated in a clinical trial and has received an investigational product within 30 days or 5 half-lives, whichever is longer.
  • Participants with excessive caffeine intake (defined as greater than [>] 6 servings [1 serving is approximately equivalent to 120 milligram [mg] of caffeine] of coffee, tea, cola or other caffeinated beverages per day) within 14 days prior to first dose.
  • The participant has known severe renal impairment ( \<30 milliliters per minute [mL/min] or clinically significant elevated serum creatinine as determined by the investigator).
  • The participant presents with (self-reported) vaginal discharge suspected for infection at Baseline.
  • The participant has congenital long QT syndrome or known prolongation of the corrected QT (QTc) interval.
  • The participant has a family history of QT prolongation or sudden death.
  • The participant has a recent history of vasovagal syncope or episodes of symptomatic bradycardia or brady arrhythmia within the last 12 months.
  • Having two or more of the following risk factors: 1. Body weight between 45 kg and 60 kg, 2. Moderate renal impairment (creatinine clearance 30 to 59 mL/min), 3. Moderate hepatic impairment ( Class B)
  • QTc >450 milliseconds (msec) or QTc >480 msec for participants with bundle branch block.
  • Severe hepatic impairment (Child Pugh Class C)
  • >1.5* (ULN).
  • Total >1.5*ULN; Participants with Gilbert's syndrome can be included with total bilirubin >1.5*ULN if direct bilirubin is \<=1.5*ULN.
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities (except for Gilbert's syndrome or asymptomatic gallstones).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    Participants receiving Gepotidacin

    Drug: Gepotidacin

Interventions

  • A single oral dose of 3000 mg gepotidacin will be administered

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve from time zero to the last measurable concentration time point (t) (AUC[0 to t]) of gepotidacin in breast milk

    Time frame: Up to 48 hours post dose

Secondary outcomes

  1. AUC(0 to t) of gepotidacin in plasma

    Time frame: Up to 48 hours post dose

  2. Maximum drug concentration (Cmax) of gepotidacin in plasma

    Time frame: Up to 48 hours post dose

  3. Area under the concentration-time curve from time zero to infinity (AUC[0 to infinity]) of gepotidacin in plasma

    Time frame: Up to 48 hours post dose

  4. AUC(0 to infinity) of gepotidacin in breast milk

    Time frame: Up to 48 hours post dose

  5. Cmax of gepotidacin in breast milk

    Time frame: Up to 48 hours post dose

  6. Concentration of gepotidacin in breast milk from time zero to the last measurable concentration time point (0 to t)

    Time frame: Up to 48 hours post dose

  7. Fraction of gepotidacin excreted in breast milk (0 to t) after a single dose administration

    Time frame: Up to 48 hours post dose

  8. Breast milk to Plasma ratio for AUC (0 to t) of gepotidacin

    Time frame: Up to 48 hours post dose

  9. Breast milk to Plasma ratio for AUC (0 to infinity) of gepotidacin

    Time frame: Up to 48 hours post dose

  10. Breast milk to Plasma ratio for Cmax of gepotidacin

    Time frame: Up to 48 hours post dose

  11. Number of participants with adverse events (AEs) and serious adverse event (SAEs)

    Time frame: Up to 14 days

07

Study locations

1 of 1 sites recruiting
  • GSK Investigational Site
    Las Vegas, Nevada 89113-2235, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for May 2027, 9 months after the start.

Of 16 phase 1 interventional studies under Urinary Tract Infections, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2026
First posted
Jun 12, 2026
StartActual
Jul 23, 2026
Primary completionEst.
May 17, 2027
CompletionEst.
May 17, 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 30, 2026
Sites
1 site added — first site in United States
Show site
  • GSK Investigational Site · Las Vegas, United States
Sep 30, 2026
Start date
Jul 9, 2026→Jul 23, 2026 (actual)
Sep 30, 2026
Primary completion
May 5, 2027→May 17, 2027
Sep 30, 2026
Study completion
May 13, 2027→May 17, 2027
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • GSK Investigational Site · Las Vegas, United States
    Start date Jul 9, 2026→Jul 23, 2026 (now actual)
    Primary completion May 5, 2027→May 17, 2027
    Study completion May 13, 2027→May 17, 2027
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07645235
Lead sponsor
GlaxoSmithKline
Collaborators
Biomedical Advanced Research and Development Authority
Responsible party
Sponsor
First posted
Jun 12, 2026
Start date
Jul 23, 2026
Primary completion
May 17, 2027 (estimated)
Completion
May 17, 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gepotidacin

Start the discussion